Bicara Therapeutics Inc. Common Stock (BCAX) Earnings Analysis
Bicara Therapeutics Inc. Common Stock (BCAX) next reports earnings on 2026-08-11, consensus EPS -0.81978 USD. Last quarter (2026-05-11) it missed with EPS -0.93 USD vs -0.64 USD est (-45.3%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -10.06.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BCAX next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.81978 USD |
| Revenue estimate | n/a |
BCAX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.93 USD | -0.64 USD | -45.3% | Miss |
| 2026-03-26 | -0.68 USD | -0.72 USD | +5.6% | Beat |
| 2025-11-10 | -0.67 USD | -0.55 USD | -21.8% | Miss |
| 2025-08-12 | -0.5 USD | -0.54 USD | +7.4% | Beat |
| 2024-09-13 | -0.27276 USD | n/a | n/a | n/a |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
BCAX valuation and analyst view
| Trailing P/E | -10.06 |
|---|---|
| Trailing EPS | -2.59095 USD |
| Price / book | 3.30 |
| Dividend yield | 0.00% |
| Market cap | 1.51B |
| Analyst consensus | Buy (5 buy / 2 hold / 0 sell) |
| Avg price target | 32.33 USD |
Related research pages
Frequently asked questions
When is Bicara Therapeutics Inc. Common Stock (BCAX)'s next earnings date?
Bicara Therapeutics Inc. Common Stock is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.81978 USD.
Did BCAX beat earnings last quarter?
In its 2026-05-11 report, BCAX posted EPS of -0.93 USD versus a -0.64 USD estimate — a miss of 45.3%.
What is BCAX's earnings track record?
Over the last 4 reported quarters with consensus data, BCAX beat estimates 2 times (50%).
What is BCAX's current P/E ratio and EPS?
BCAX trades at a trailing P/E of -10.06 on trailing EPS of -2.590953007739623 USD.
What do analysts rate BCAX?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 32.33 USD.